Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain.
about
Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensationGuidelines on the irritable bowel syndrome: mechanisms and practical management.Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial.
P2860
Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Challenges in drug development ...... rders. Part II: visceral pain.
@ast
Challenges in drug development ...... rders. Part II: visceral pain.
@en
type
label
Challenges in drug development ...... rders. Part II: visceral pain.
@ast
Challenges in drug development ...... rders. Part II: visceral pain.
@en
prefLabel
Challenges in drug development ...... rders. Part II: visceral pain.
@ast
Challenges in drug development ...... rders. Part II: visceral pain.
@en
P2860
P1476
Challenges in drug development ...... rders. Part II: visceral pain.
@en
P2093
Andresen V
Camilleri M
P2860
P304
P356
10.1111/J.1365-2982.2006.00779.X
P577
2006-05-01T00:00:00Z